
One Step Closer to Treatment with Raena and Frank Vrtochnick
18 Nov 2026 · 20:36
Life SciencesDescription
The Vrtochnick family recalls the moment they were told that their son’s investigational new drug application (IND) received a “may proceed” authorization from the FDA, meaning that a green light has been signaled for Gunnar to receive his ASO medicine charitably created by n-Lorem. Gunnar, a pre-teen from Wisconsin, lives with KIF1A-Associated Neurological Disorder (KAND) which causes him difficulties with spasticity and motor function. With this authorization, he hopes to begin treatment in the coming months.
Hear about Gunnar's diagnosis, what a treatment means for his family, the community impact of the colloquium, and more in this Patient Empowerment Program podcast episode.
In this episode we discuss:
1:30 - Involvement in Rescue 7 and it becoming a colloquium staple for families
2:35 – Meet the Vrtochnick family
3:00 – Community impact of the Colloquium and meeting others facing similar difficulties
4:07 – Gunnar's symptoms and diagnosis
5:30 – What an n-Lorem discovered, developed, and charitably provided ASO medicine means to their family
7:48 – The moment they were told that their son's IND received a "May proceed" authorization from the FDA
11:43 – Gunnar's interests and him learning the importance of giving back
---
Links:
Sponsors:
Comments
No comments yet — be the first to write one.